Arca
Skip to content
Tools
Tools

MAOB: Amine oxidase [flavin-containing] B

Catalyzes the oxidative deamination of primary and some secondary amines such as neurotransmitters, and exogenous amines including the tertiary amine, neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP), with concomitant reduction of oxygen to hydrogen peroxide and participates in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues.

  • Drugs that act on it: 4
  • Approved: 3
  • In phases 1 to 3: 1
  • Sponsors: 4

Who is on it, and how far along

Every drug ChEMBL records acting on MAOB, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 4

Approved3

  • Safinamide
  • Rasagiline
  • Selegiline

Phase 31

  • Ralfinamide

Phase 20

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Monoamine oxidase B inhibitor.
      SafinamideApprovedMDD USSmall moleculeInhibitor2
      RasagilineApprovedTeva Pharmaceutical IndustriesSmall moleculeInhibitor1
      SelegilineBoxed warningApprovedSomerset TherapeuticsSmall moleculeInhibitor0
      RalfinamidePhase 3Newron Pharmaceuticals SPASmall moleculeInhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.
      Safinamide vs Placebo for Pain in Patients With Parkinson's Disease and Motor FluctuationsSafinamidePhase 3RecruitingUniversita di VeronaAug 13, 2026
      Fall Risk Assessment in Parkinson's Disease Using Kinetikos HealthSafinamide—Not yet recruitingTaipei Medical University Shuang Ho HospitalDec 2, 2025
      Relative Bioavailability Study of HNC364 Injectable SuspensionRasagilinePhase 1Active, not recruitingGuangzhou Henovcom Bioscience Co. Ltd.Jan 29, 2025

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      Parkinson disease
      0.63
      Hypertensive disorder
      0.47
      Melancholia
      0.37
      Neurodegenerative disease
      0.31
      Cocaine dependence
      0.29
      Postural instability
      0.26

      Genes and related targets

      Complexes and families that share a gene with this target
      Genes
      MAOB

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2039, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P27338, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.